India, Oct. 1 -- Monte Rosa Therapeutics (GLUE) said it will present clinical results today, October 1, 2026 from the GFORCE-1 Phase 1 study of MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk.
MRT-8102 is a NEK7-directed molecular glue degrader designed to target inflammatory pathways associated with atherosclerotic cardiovascular disease (ASCVD).
According to the company, the presentation will include safety and activity data across multiple dose levels following 4 weeks of treatment and will highlight MRT-8102's effects on multiple pathogenic drivers of cardiovascular disease.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
The results will be discussed during a webcast and con...